Increasing the rate of late toxicity by changing the score? A comparison of RTOG/EORTC and LENT/SOMA scores.

PURPOSE The Radiation Therapy Oncology Group (RTOG) and Late Effects Normal Tissue Task Force subjective, objective, management, and analytic (LENT/SOMA) scores were compared in a group of breast cancer patients. The impact of the classification system on grading late effects was evaluated. MATERIALS AND METHODS Telangiectasia, skin pigmentation, and fibrosis were scored according to both LENT/SOMA and RTOG criteria. The results were compared with respect to up- or downgrading and correlated (Spearman's rho). Other side effects were recorded using LENT/SOMA criteria. Interobserver variability was calculated with Cohen's kappa. Two hundred fifty-nine subsequent relapse-free patients who underwent breast-conserving therapy between 1981 and 1995 were examined. The median dose of radiotherapy to the breast was 55 Gy. Adjuvant chemotherapy was given to 31 patients and tamoxifen to 52 patients. The median follow-up was 8 years. RTOG skin and s.c. tissue scales and LENT/SOMA breast and pigmentation scales were used. Two doctors examined 45 patients jointly. RESULTS Of all patients, 20% had telangiectasia, 22% pigmentation, 43% fibrosis, 4% breast edema, 77% retraction/atrophy, and 54% pain. In comparison, when LENT/SOMA criteria were used, telangiectasia and pigmentation were upgraded in 34% and 36%, respectively, and telangiectasia was downgraded in 45%. Fibrosis correlated well (Spearman's rho 0.78, p = 0.01). An additional 356 side effects, mainly retraction/atrophy were observed in 226 patients using LENT/SOMA criteria. Interobserver variability was similar for both classification systems and ranged from Cohen's kappa 0.3 (retraction) to 0.91 (telangiectasia). CONCLUSIONS LENT/SOMA criteria seem to be the better tool in grading and recording late radiation toxicity compared with the RTOG scale. There was some upgrading with the RTOG score when skin toxicity is evaluated. In contrast, fibrosis scores correlated very well. Adjustments of the LENT/SOMA scoring system should be considered to standardize reporting of late radiation morbidity.

[1]  H. Bartelink,et al.  Correction for the use of the SOMA LENT tables. , 1996, International journal of radiation oncology, biology, physics.

[2]  T. Pajak,et al.  LENT: a good beginning but... , 1995, International journal of radiation oncology, biology, physics.

[3]  J. Overgaard,et al.  Late Treatment-Related Morbidity in Breast Cancer Patients Randomized to Postmastectomy Radiotherapy and Systemic Treatment Versus Systemic Treatment Alone , 2000 .

[4]  Jacques Bernier,et al.  Late effects toxicity scoring: the SOMA scale , 1995 .

[5]  M. Seegenschmiedt.  Nebenwirkungen in der Onkologie , 1998 .

[6]  A. Haydaroǧlu,et al.  Late radiation effects to the rectum and bladder in gynecologic cancer patients: the comparison of LENT/SOMA and RTOG/EORTC late-effects scoring systems. , 2001, International journal of radiation oncology, biology, physics.

[7]  P. Rubin,et al.  RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. , 1995, International journal of radiation oncology, biology, physics.

[8]  A. Hanlon,et al.  Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. , 1997, International journal of radiation oncology, biology, physics.

[9]  L. Gras,et al.  Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. , 1998, International journal of radiation oncology, biology, physics.

[10]  A. Stanton,et al.  Form or function? Part 1. Subjective cosmetic and functional correlates of quality of life in women treated with breast‐conserving surgical procedures and radiotherapy , 2001, Cancer.

[11]  P. Rubin,et al.  EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.